MOLECULAR TEMPLATES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.45 USD | -2.68% |
|
-9.38% | -61.13% |
Presenter SpeechEric Poma (Executives)All right. I think we're ready to start. So I want to st...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Companyâs proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.45
USD
Average target price
18
USD
Spread / Average Target
+1,141.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -61.13% | 9.55M | |
| +7.52% | 113B | |
| +11.38% | 106B | |
| +1.02% | 22.27B | |
| -12.64% | 22.22B | |
| -5.24% | 19.43B | |
| -37.85% | 17.87B | |
| -8.58% | 17.24B | |
| +7.77% | 14.29B | |
| +37.41% | 12.52B |
- Stock Market
- Equities
- MTEM Stock
- News Molecular Templates, Inc.
- Transcript : Molecular Templates, Inc. - Shareholder/Analyst Call
